日科化学(300214) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 735,574,870.44, representing a 27.27% increase compared to CNY 577,964,663.37 in the same period last year[4] - Net profit attributable to shareholders for Q1 2022 was CNY 80,938,188.27, a significant increase of 111.61% from CNY 38,249,194.58 in Q1 2021[4] - The basic earnings per share for Q1 2022 was CNY 0.17, up 88.89% from CNY 0.09 in the previous year[4] - The total operating revenue for the first quarter of 2022 was CNY 735,574,870.44, an increase of 27.3% compared to CNY 577,964,663.37 in the same period last year[24] - The net profit for the first quarter was CNY 80,938,188.27, representing a significant increase of 111.2% compared to CNY 38,249,194.58 in the previous year[26] - The operating profit reached CNY 101,566,530.76, which is a 105.5% increase from CNY 49,400,505.90 in the same quarter last year[24] - The company reported a total comprehensive income of CNY 80,938,188.27, which is a 111.2% increase from CNY 38,249,194.58 in the previous year[26] Assets and Liabilities - Total assets at the end of Q1 2022 reached CNY 2,943,114,096.11, marking a 27.71% increase from CNY 2,304,596,450.06 at the end of the previous year[4] - The total equity attributable to shareholders at the end of Q1 2022 was CNY 2,443,626,960.95, an increase of 26.91% from CNY 1,925,525,392.54 at the end of the previous year[4] - Current assets reached CNY 1,765,002,294.87, up from CNY 1,726,934,000.69 at the start of the year, indicating a growth of approximately 2.2%[22] - The total liabilities stood at CNY 1,765,002,294.87, reflecting a significant increase compared to the previous period[22] - The total liabilities decreased to CNY 499,487,135.16 from CNY 531,064,764.46, reflecting a reduction of 5.9%[24] Cash Flow - The net cash flow from operating activities for Q1 2022 was CNY 10,059,329.13, a decrease of 64.68% compared to CNY 28,476,786.38 in Q1 2021[13] - The company's cash flow from investing activities for Q1 2022 was CNY 60,468,260.70, a significant improvement compared to a negative cash flow of CNY 14,698,054.86 in the same period last year[13] - The net cash flow from investment activities was ¥60,468,260.70, recovering from a negative cash flow of ¥14,698,054.86 in Q1 2021[29] - The total cash outflow from operating activities was ¥626,786,349.02, compared to ¥490,426,857.98 in Q1 2021[29] Research and Development - Research and development expenses increased by 78.85% to CNY 5,207,161.76 in Q1 2022, reflecting the company's commitment to enhancing technological innovation[11] - Research and development expenses were CNY 5,207,161.76, which is an increase of 78.6% compared to CNY 2,911,416.12 in the previous year[24] Shareholder Information - The company reported a total of 106,338,778 restricted shares, with 45,000,000 shares released during the period[19] - The company has a commitment to not transfer more than 25% of shares held during the tenure of executives, with restrictions lasting for six months post-employment[18] - The company is actively engaged in non-public offerings, with specific commitments to lock-up periods for certain shareholders[19] Cash and Equivalents - Cash and cash equivalents increased to CNY 164,725,545.96 from CNY 89,689,738.95, representing an increase of 83.6%[21] - Cash received from sales of goods and services was CNY 623,751,159.37, an increase of 21.9% compared to CNY 511,718,347.86 in the same period last year[28] - Cash and cash equivalents at the end of Q1 2022 amounted to ¥152,840,054.13, an increase from ¥77,804,910.74 at the beginning of the quarter[30] - The net increase in cash and cash equivalents for the quarter was ¥75,035,143.39, compared to a decrease of ¥21,215,524.97 in Q1 2021[30]